<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377230</url>
  </required_header>
  <id_info>
    <org_study_id>Garcilaso-Mex 20-3</org_study_id>
    <nct_id>NCT04377230</nct_id>
  </id_info>
  <brief_title>BP Limb Length of 60cm vs 100cm in Roux-en-Y Gastric Bypass</brief_title>
  <official_title>Impact of Biliopancreatic Limb Length of 60cm vs 100cm in Roux-en-Y Gastric Bypass on Bone Mineral Density 2 Years After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Seguridad Social del Estado de Mexico y Municipios</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized into 2 groups:

        -  Group 60: Patients will undergo a Roux-en-Y gastric bypass with a Biliopancreatic limb
           length of 60cm

        -  Group 100: Patients will undergo a Roux-en-Y gastric bypass with a Biliopancreatic limb
           length of 100cm

      Bone mineral density will be evaluated before surgery and 2 years after it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into 2 groups:

        -  Group 60: Patients will undergo a Roux-en-Y gastric bypass with a Biliopancreatic limb
           length of 60cm

        -  Group 100: Patients will undergo a Roux-en-Y gastric bypass with a Biliopancreatic limb
           length of 100cm Alimentary limb will be constant in both groups (150cm length)

      Bone mineral density will be evaluated before surgery and 2 years after it, by means of X ray
      absorptiometry (DEXA). Changes in bone mineral density in lumbar column will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 7, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The radiologist evaluating bone mineral density will be blinded to the biliopancreatic limb length</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Bone mineral density will be evealuated by absorptiometry at the level of lumbar column</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Biliopancreatic limb 60cm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliopancreatic limb 100cm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biliopancreatic limb length of 60cm.</intervention_name>
    <description>Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.</description>
    <arm_group_label>Biliopancreatic limb 60cm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biliopancreatic limb length of 100cm.</intervention_name>
    <description>Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.</description>
    <arm_group_label>Biliopancreatic limb 100cm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index &gt;40 Kg/m2

          -  Body mass index &gt;35 Kg/m2 associated to obesity related comorbidities

        Exclusion Criteria:

          -  Bone pathologies

          -  Active neoplasms

          -  Disorders in calcium or vitamin D metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Ruiz-Tovar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Garcilaso Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina LLavero Garrido</last_name>
    <phone>649593020</phone>
    <email>carolinallavero@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilberto Gonzalez</last_name>
    <phone>+5213322545864</phone>
    <email>gilpchmd@yahoo.com.mx</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Elche</investigator_affiliation>
    <investigator_full_name>Jaime Ruiz-Tovar, MD, PhD</investigator_full_name>
    <investigator_title>Department of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

